Results 41 to 50 of about 169 (166)

Alzheimer's Biomarkers and Visuospatial Cognition in Parkinson's Disease: Modification by α‐Synuclein and Mediation of Age Effects

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Visuospatial deficits in Parkinson's disease (PD) often precede dementia and complicate daily functioning. Alzheimer's disease (AD) pathology and α‐synuclein aggregation frequently co‐occur in PD, but their combined impact on cognition is unclear.
David Ledingham   +8 more
wiley   +1 more source

Exocrine Gland Dysfunction in Parkinson's Disease: Pathophysiology, Clinical Manifestations, and Therapeutic Perspectives—A Narrative Review

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Non‐motor symptoms, especially autonomic dysfunction, are major contributors to disability and decreased quality of life in Parkinson's disease (PD). Despite being common and having a wide range of clinical facets, exocrine gland dysfunction is still not well recognized and managed.
Renato P. Munhoz   +2 more
wiley   +1 more source

From Molecular Pathology to Cognitive Phenotypes: The Emerging Role of Artificial Intelligence in Neuroimaging

open access: yes
iRADIOLOGY, EarlyView.
Xiaohui Zhang   +6 more
wiley   +1 more source

Clinical Progression in Alpha‐Synuclein Positive LRRK2‐PD and Sporadic Parkinson's Disease: A Longitudinal Analysis

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background LRRK2‐Parkinson's disease (LRRK2‐PD) is biologically heterogeneous with approximately 30% lacking aggregated alpha synuclein (αSyn) in cerebrospinal fluid by seed amplification assay (SAA). Prior work has suggested slower progression in LRRK2‐PD compared to sporadic PD (sPD).
Lucy A. Morse   +224 more
wiley   +1 more source

Mind the Gap: Predictors of Osteoporosis Treatment Following Fragility Fracture in Parkinsonism

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Fracture risk is increased in Parkinson's yet this risk is often not addressed. Objectives Our objective was to study the extent to which osteoporosis was treated, and predictors of treatment in a large representative cohort with parkinsonism.
Katie C. Naylor   +2 more
wiley   +1 more source

Enteral Nutrition in Idiopathic Parkinson's Disease and Atypical Parkinsonism: A Systematic Review

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Dysphagia and malnutrition are common in advanced Parkinson's disease and atypical parkinsonism. There is a lack of evidence to guide the use of enteral nutrition in these situations, including whether it improves survival or reduces aspiration pneumonia.
Bradley Lonergan   +3 more
wiley   +1 more source

Cardiac MIBG Scintigraphy in Neurodegenerative Parkinsonism: Limitations in Clinical Practice

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Reduced cardiac uptake on 123Iodine‐metaiodobenzylguanidine (MIBG) scintigraphy is a valuable tool for differentiating neurodegenerative parkinsonism but interpretation can be difficult due to comorbidities and drug‐tracer interactions.
Frank Jagusch   +9 more
wiley   +1 more source

Diagnostic Value of Bedside Eye Movement Examination in Movement Disorders

open access: yes
Movement Disorders Clinical Practice, EarlyView.
Eloísa Bittencurt Thomaz de Assis   +4 more
wiley   +1 more source

Tracking Genetic Parkinson's Disease with Molecular Imaging: A Systematic Review

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease (PD) is a worldwide, complex neurodegenerative disorder influenced by both genetic and environmental factors. Around 15–20% of PD cases are linked to genetic mutations, providing insights into the disease's pathogenesis.
Chiara Meneghini   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy